This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
To the Editor.—
I would like to contradict the recent letter to the editor (227:79, 1974) by Stephen J. Rush, MD, of Winthrop Laboratories who stated that "the severe sclerosis of the skin and subcutaneous tissues discussed by Winfield and Greer is rare and has occurred, almost without exception, in patients who have taken pentazocine for long periods of time in a dosage far greater than that recommended by Winthrop or approved by the Food and Drug Administration." We have seen half a dozen patients at our Center who had been taking pentazocine (Talwin) intramuscularly for periods less than three months; in four of them, we had reasonably good substantiation that they had not exceeded the recommended dosage in their administration of the drug. The other two patients we had some doubts about, but we were still convinced that their dosage was not extremely high.All of the patients had
Beckner TF. Pentazocine Problems. JAMA. 1974;227(12):1383. doi:10.1001/jama.1974.03230250015017
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: